<DOC>
	<DOCNO>NCT01023178</DOCNO>
	<brief_summary>To directly compare safety ( laboratory evaluation ) efficacy ( feminization growth ) three commonly use estrogen preparation adolescent patient ovarian failure , either due congenital cause ( Turner syndrome ) medical therapy . We hypothesize transdermal estrogen equivalent efficacy favorable safety profile comparison conventional oral estrogen replacement .</brief_summary>
	<brief_title>Comparison Transdermal Oral Estrogens Adolescent Girls With Ovarian Failure</brief_title>
	<detailed_description>Treatment transdermal 17beta ( 17Î² ) estradiol result high estradiol level effective feminization compare oral conjugate equine estrogen result otherwise different biochemical profile limit number heterogeneous patient . OBE ( oral beta estradiol ) TBE ( transdermal beta estradiol ) provide safe effective alternative OCEE ( oral conjugate equine estrogen ) induce puberty girl , large prospective randomize trial require .</detailed_description>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>initiation estrogen therapy recommend due ovarian failure Outpatients age &gt; =12 year 17.99 year old spontaneous menses significant concurrent medical problem include : Liver function test ( LFTs ) 3 time normal clot disorder ongoing cancer treatment</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>